Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22439019 | 0.89 | DEGS1 (0.43) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL30070869 | 0.88 | DEGS1 (0.40) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL22439086 | 0.88 | DEGS1 (0.40) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL22439054 | 0.85 | DEGS1 (0.46) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL22438882 | 0.85 | MAP4K4 (0.46) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL23908262 | 0.84 | EGLN1 (0.50) | MAP4K4MINK1TNIKDEGS1EGLN1 | |
| SCHEMBL22438845 | 0.82 | CXCR3 (0.42) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL22439074 | 0.82 | CXCR3 (0.43) | MAP4K4MINK1TNIKDEGS1EGLN1 | |
| SCHEMBL22439274 | 0.82 | MAP4K4 (0.43) | MAP4K4MINK1TNIKDEGS1XDH | |
| SCHEMBL22438582 | 0.81 | CXCR3 (0.43) | MAP4K4MINK1TNIKDEGS1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3709986-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-11498904-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | claimed |
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3709986-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3709986-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11498904-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | MAP4K4 3490/4885MINK1 946/4885TNIK 2300/4885 |
| US-11498904-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | MAP4K4 3403/4885MINK1 1312/4885TNIK 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.